Analysts and investors alike will be keeping a close eye on the performance of Hercules Capital in its upcoming earnings disclosure. In that report, analysts expect Hercules Capital to post earnings of $0.51 per share. This would mark a year-over-year decline of 3.77%. Meanwhile, the latest consensus estimate predicts the revenue to be $124.99 million, indicating a 7.53% increase compared to the same quarter of the previous year. Our research shows that these estimate changes are directly correlated with ne ...

Prior to today's trading, shares of the specialty finance company had gained 4.08% over the past month. This has outpaced the Finance sector's loss of 0.57% and the S&P 500's gain of 3.38% in that time. In terms of valuation, Hercules Capital is currently trading at a Forward P/E ratio of 9.78. This valuation marks a premium compared to its industry's average Forward P/E of 8.2. In the latest trading session, Hercules Capital (HTGC) closed at $20.28, marking a +0.65% move from the previous day. The stock ex ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Hercules Capital currently has an average brokerage recommendation (ABR) of 1.89, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by nine brokerage firms. A ...

Hercules Capital (HTGC) ended the recent trading session at $19.82, demonstrating a +0.1% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 0.16%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq lost 0.18%. The investment community will be closely monitoring the performance of Hercules Capital in its forthcoming earnings report. The company is predicted to post an EPS of $0.51, indicating a 3.77% decline compared to the equivalent ...

Analysts and investors alike will be keeping a close eye on the performance of Hercules Capital in its upcoming earnings disclosure. In that report, analysts expect Hercules Capital to post earnings of $0.51 per share. This would mark a year-over-year decline of 3.77%. Meanwhile, our latest consensus estimate is calling for revenue of $124.99 million, up 7.53% from the prior-year quarter. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on thi ...

The yield is big, but as always, there are trade-offs to consider before diving in. Like dividends? A little outfit called Hercules Capital (HTGC -1.31%) dishes them out in a big way. Shares of this business development company boast a trailing dividend yield of a little over 8%, in fact, and that's based on just its ordinary quarterly payout. Adding its supplemental dividend to the mix cranks the trailing-12-month yield up to nearly 10%. Not bad. Before plowing into a new stake in this name based on nothin ...

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Hercules Capital (HTGC) closed the most recent trading day at $19.60, moving -1.31% from the previous trading session. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a drop of 0.17%, and the ...

Shares of the specialty finance company witnessed a loss of 0.45% over the previous month, trailing the performance of the Finance sector with its gain of 1.22% and the S&P 500's gain of 3.51%. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.06 per share and revenue of $503.7 million, indicating changes of -0.96% and +9.34%, respectively, compared to the previous year. Our research reveals that these estimate alterations are directly linked with the stock price performance i ...

$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has completed the sale of its Rare Pediatric Disease Priority Review ...

Meet the high-yield dividend payers that could raise your passive income stream.Investors eager to bulk up their passive income streams can do so without breaking the bank.At recent prices, Hercules Capital (HTGC 1.29%), Altria Group (MO -0.23%), and AT&T (T 0.83%) offer an average yield of 8.5% at recent prices. That's high enough to turn an initial investment of $5,890 into $500 of annual dividend income.There are plenty of dividend stocks with even higher yields right now. These three stand out because t ...